Theratechnologies is pepped up on peptides. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. Lead drug EGRIFTA (tesamorelin for injection) is being marketed for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Theratechnologies received US approval for EGRIFTS in 2010 and approval in Canada and Mexico in 2015. The drug is marketed solely in the US (in partnership with inVentiv Health) and Canada. It is seeking to market EGRIFTA elsewhere around the world through partnerships with Sanofi, AOP Orphan Pharmaceuticals, and BL&H Co.